Key Findings
- Purpose
To evaluate the efficacy and safety of etavopivat, a selective activator of red blood cell pyruvate kinase, in patients with sickle cell disease (SCD). Etavopivat improves red cell energy metabolism by increasing ATP and decreasing 2,3-DPG levels. - Population (Model)
Randomized, double-blind, placebo-controlled Phase 2 trial including 60 participants aged 12–65 years with SCD and 2–10 prior vaso-occlusive crises. Participants were randomized to etavopivat 200 mg (n=21), 400 mg (n=20), or placebo (n=19) for 52 weeks. Mean age was 33.5 years and baseline hemoglobin averaged 8.4 g/dL; approximately 90% had HbSS genotype. Concomitant hydroxyurea was used by 65–76% of participants.
- Headline Result
- Annualized VOC rates (ITT population): 1.07 (200 mg) and 1.06 (400 mg) vs 1.97 with placebo (~46% reduction).
- Per-protocol analysis: VOC rate ratios vs placebo showed ~63% and ~61% reductions with the 200 mg and 400 mg doses, respectively.
- Hemoglobin response (>1 g/dL at Week 24): 38% (200 mg), 25% (400 mg), vs 11% placebo; mean Hb change at Week 24 was +1.11 g/dL (200 mg) and +0.73 g/dL (400 mg) vs +0.15 g/dL placebo.
- Time to first VOC: 33.6 weeks with etavopivat vs 16.9 weeks with placebo.
- Hemolysis biomarkers (reticulocytes, bilirubin, LDH) improved and LDH reductions persisted through Week 52; patient-reported fatigue scores also improved.
- Why It Matters
Etavopivat targets red cell metabolic dysfunction, offering a mechanism distinct from hemoglobin polymerization inhibitors or adhesion-targeted therapies. Improvements in VOC rates, hemoglobin levels, hemolysis markers, and fatigue suggest a potential disease-modifying role for metabolic modulation of RBC function. - Evidence Gaps & Limitations
Phase 2 cohort with modest sample size; statistical confidence intervals around VOC reductions were wide. Larger Phase 3 trials are needed to confirm clinical benefit and evaluate long-term safety.
Source: Journal of Sickle Cell Disease- “Etavopivat Reduces Incidence of Vaso-occlusive Crises in Patients With Sickle Cell Disease: Hibiscus Trial Phase 2 Results through 52 Weeks”
Regulatory & Guideline Watch
Current SCD treatment guidelines emphasize hydroxyurea, transfusion therapy, and recently approved disease-modifying agents. Therapies targeting red cell metabolic pathways represent an emerging class that may broaden future treatment strategies pending confirmatory trials.